New drug shows promise for stopping deadly seizures
NCT ID NCT02052739
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called SAGE-547 in 25 people with super-refractory status epilepticus, a condition where seizures continue despite standard treatments. The goal was to see if the drug is safe and tolerable. Participants received the drug by IV infusion, and researchers monitored for side effects and changes in health. The study is completed, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAGE-547 (a drug given by IV infusion)
- What this could lead to
- If it works, this could provide a new treatment option for people with super-refractory status epilepticus, a life-threatening seizure condition that doesn't respond to standard drugs.
- What could go wrong
- This was a small, early-phase study (Phase 1/2) with only 25 participants, focused mainly on safety. It may not show clear benefit, and the drug could have side effects. More research is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPER-REFRACTORY STATUS EPILEPTICUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sage Investigational Site
Birmingham, Alabama, 35294, United States
-
Sage Investigational Site
Sarasota, Florida, 34239, United States
-
Sage Investigational Site
Chicago, Illinois, 60611, United States
-
Sage Investigational Site
Wichita, Kansas, 67214, United States
-
Sage Investigational Site
New Orleans, Louisiana, 70121, United States
-
Sage Investigational Site
Boston, Massachusetts, 02114, United States
-
Sage Investigational Site
Boston, Massachusetts, 02115, United States
-
Sage Investigational Site
Ann Arbor, Michigan, 48109, United States
-
Sage Investigational Site
Detroit, Michigan, 48322, United States
-
Sage Investigational Site
New York, New York, 10032, United States
-
Sage Investigational Site
Rochester, New York, 14642, United States
-
Sage Investigational Site
Durham, North Carolina, 27710, United States
-
Sage Investigational Site
Winston-Salem, North Carolina, 27157, United States
-
Sage Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
Sage Investigational Site
Nashville, Tennessee, 37232, United States
-
Sage Investigational Site
Dallas, Texas, 75251, United States
-
Sage Investigational Site
Temple, Texas, 76504, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.